Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2695825 | 0.86 | TSHR (0.54) | TSHRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL26455588 | 0.84 | CYP2D6 (0.37) | TSHRCYP2D6 | |
| SCHEMBL31042696 | 0.84 | TSHR (0.40) | TSHRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL24842172 | 0.82 | CYP2D6 (0.36) | TSHRCYP2D6 | |
| SCHEMBL29320463 | 0.82 | TSHR (0.41) | TSHRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10201616 | 0.82 | TSHR (0.46) | TSHRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22752339 | 0.80 | TSHR (0.65) | TSHRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13656164 | 0.78 | CYP2D6 (0.34) | CYP2D6 | |
| SCHEMBL26455582 | 0.78 | TSHR (0.36) | TSHRCYP2D6 | |
| SCHEMBL21499005 | 0.78 | TSHR (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288931-B1 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2019-11-06 | — | — | EP | disclosed |
| US-10450316-B2 | Certain protein kinase inhibitor | Chongqing Fochon Pharmaceutical Co., Ltd. (CN) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450316-B2 | Certain protein kinase inhibitor | CDK4, CDK6, CDK2 | TSHR 2868/4885CYP3A4 3365/4885CYP2D6 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.